Le Lézard
Classified in: Health, Science and technology
Subject: PER

Slone Partners Places Mike Spigarelli as Chief Medical Officer at Lumen Bioscience


SOUTH RIDING, Va., Sept. 29, 2020 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and diagnostics companies, has announced the placement of Mike Spigarelli MD, PhD, MBA as Chief Medical Officer (CMO) at Lumen Bioscience. As CMO, Dr. Spigarelli will help advance Lumen Bio's impressive clinical pipeline.

Dr. Spigarelli brings more than 30 years of experience in clinical product development, including trial design, implementation, data analysis, and oversight to his new role. He is also an experienced practitioner in medical research and development, scientific research, and clinical leadership and education. Spigarelli most recently served as Vice President of Medical Affairs at Immucor, Inc., where he helped develop and obtain FDA and global regulatory approval for numerous assays and reagents and led the company's global clinical affairs and assay development teams. Prior to Immucor, he partnered with numerous drug, device, and diagnostic development companies on clinical trial design, site selection, and regulatory strategy.

Incorporated in 2017, Lumen Bio is a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases. Lumen Bio's clinical pipeline includes investigational biologics for traveler's diarrhea, norovirus, and C. difficile infection.

"As an extremely skilled industry leader with three decades of medical, pharmaceutical, and academic experience, Mike Spigarelli has a thorough understanding of clinical affairs, drug development, and regulatory strategy," said Slone Partners President Tara Kochis-Stach. "He will be a tremendously valuable addition to the Lumen Bio executive team at a time when the company is advancing a number of exciting new investigational biologic drugs."

Spigarelli earned an MBA at the University of Utah, and a PhD in Medical Chemistry and MD with Distinction in Research from the University of Michigan in Ann Arbor.

ABOUT SLONE PARTNERS
Slone Partners delivers the leaders who build amazing scientific healthcare organizations ? People Are Our Science®. Since 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established life sciences, biotech, diagnostics, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, New York, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services to innovative scientific healthcare companies. To learn more about Slone Partners' value proposition and processes, http://www.slonepartners.com or call 888.784.3422.

 

SOURCE Slone Partners


These press releases may also interest you

at 05:30
Children's Minnesota is thrilled to announce the 32nd annual Star Gala raised $2.3 million to benefit the nonprofit pediatric health system's neuroscience program. Star Gala is regarded as one of the biggest nights of the year for the Twin Cities...

at 04:04
The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical...

at 03:30
Proprietary E3 ligase platform to enable protein stabilisation "at source", thereby restoring the body's sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges...

at 03:00
Todd Britten, DMD, a board-certified periodontist and dental implant specialist in...

at 03:00
SK chemicals (CEO Ahn Jae-hyun), Dongsung Chemical (Co-CEOs Baek Jin-woo and Lee Man-woo), and BYN Black Yak (Chairman Kang Tae-sun, hereinafter Black Yak) announced on the 18th that they've developed sustainable footwear materials using the...

at 02:55
First quarter  Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas.Sales per business area, in local currencies was...



News published on and distributed by: